Real world data (RWD), which is data from actual patient treatments, provides valuable information on safety and effectiveness of innovative ...
The U.S. Food and Drug Administration (FDA) published the draft guidance “Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices,” which provides advice for ...
The US Food and Drug Administration has released draft guidance on protocol deviations, but experts say it could go further.
Tissue biopsies can be important parts of testing new drugs, and the FDA has now issued a draft guidance with recommendations for when they should be included in clinical trial protocols.
Protocol deviations ... The US Food and Drug Administration (FDA) released draft guidance in December 2024, with the agency urging sponsors, investigators, clinical research organisations (CROs ...